Neuropathy Screening and Diagnosis Market Set to Reach US$7.1 Billion by 2031 | Investment Opportunities, Growth, Trends, and Forecast 2031

The Global Neuropathy Screening and Diagnosis Market reached US$ 4.2 billion in 2023 and is expected to reach US$ 7.1 billion by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.

According to DataM Intelligence has published a new research report on "Neuropathy Screening and Diagnosis Market Size 2026". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The Neuropathy Screening and Diagnosis Market refers to the global industry focused on the development, production, and adoption of medical technologies, devices, and diagnostic methods used to detect, assess, and monitor nerve damage (neuropathy). This includes tools such as nerve conduction studies (NCS), electromyography (EMG), quantitative sensory testing (QST), imaging techniques, and emerging AI-based and point-of-care diagnostic solutions.

The market encompasses healthcare providers, diagnostic laboratories, and medical device companies that aim to enable early detection and accurate diagnosis of neuropathic conditions particularly those associated with chronic diseases like diabetes thereby improving patient outcomes and supporting effective disease management.

📌 Request Executive Market Intelligence Sample:- https://datamintelligence.com/download-sample/neuropathy-screening-and-diagnosis-market?rk

➣ Recent Developments:

✅ February 2026: Medtronic plc advanced its digital neurology portfolio by integrating AI-driven analytics into wearable nerve monitoring systems. These solutions enable continuous assessment of peripheral nerve function, supporting early detection of diabetic neuropathy-especially critical as nearly 50% of diabetes patients develop neuropathy.

✅ January 2026: Siemens Healthineers AG introduced next-generation automated nerve conduction testing platforms with enhanced data integration and cloud connectivity. These systems reduce diagnostic time while improving reproducibility, aligning with the growing demand for efficient outpatient neuropathy diagnostics.

✅ March 2026: NeuroMetrix Inc. expanded its point-of-care neuropathy screening solutions with portable, non-invasive devices designed for primary care and remote settings. This reflects the broader industry shift toward decentralized diagnostics and rapid screening tools.

✅ February 2026: The adoption of AI-based corneal confocal microscopy (CCM) gained traction, with new deep learning models improving diagnostic accuracy for small fiber neuropathy. These technologies enhance early-stage detection by analyzing corneal nerve structures with higher precision, addressing limitations of traditional diagnostic methods.

Mergers & Acquisitions:

✅ March 2026: Abbott Laboratories acquired a digital health startup specializing in AI-enabled neuropathy risk prediction platforms. This move strengthens its diabetes care ecosystem by integrating early complication screening tools.

✅ February 2026: Philips Healthcare acquired a neurodiagnostic software provider to enhance its connected care and neurological diagnostics portfolio, focusing on real-time data analytics and remote patient monitoring.

✅ January 2026: GE HealthCare completed the acquisition of a portable electrophysiology device manufacturer, aiming to expand access to nerve conduction diagnostics in emerging and rural healthcare markets.

✅ February 2026: Roche Diagnostics invested in a biomarker-based diagnostics firm to accelerate the development of precision diagnostics for neuropathy, supporting the shift toward personalized and predictive healthcare models.

📌 Request Customized Intelligence Aligned to Your Business Strategy: https://datamintelligence.com/customize/neuropathy-screening-and-diagnosis-market?rk

➣ Top Industry Players:

Eli Lilly And Company
Reddy's Laboratories
Pfizer Inc.
Cipla
Abbott Laboratories
Lupin Ltd.
NeuroBo Pharmaceuticals Inc.
NeuroMetrix Inc.
Glenmark Pharmaceuticals
Teva Pharmaceuticals
➣ Market Segments:

By Disease Type
The market is segmented into autonomic neuropathy, diabetic neuropathy, peripheral neuropathy, focal neuropathy, and polyneuropathy. Diabetic neuropathy holds a significant share due to the rising global prevalence of diabetes. Peripheral and polyneuropathy are also widely diagnosed conditions, while autonomic and focal neuropathies represent specialized segments requiring targeted diagnostic approaches.

By Diagnosis Test
Based on diagnosis test, the market includes sensory testing, nerve conduction testing, electromyography, autonomic testing, skin biopsy, MRI scanning, and others. Nerve conduction testing and electromyography dominate due to their accuracy in assessing nerve function and muscle activity. MRI scanning and skin biopsy are used for advanced diagnosis, while sensory and autonomic testing support early detection and evaluation of nerve damage.

By End-User
The market is segmented into hospitals, neurology clinics, academic and research institutes, and others. Hospitals account for the largest share due to advanced diagnostic infrastructure and high patient inflow. Neurology clinics specialize in nerve-related disorders and are growing steadily, while academic and research institutes contribute through clinical studies and development of advanced diagnostic techniques.

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Neuropathy Screening and Diagnosis Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

📌 Purchase Corporate License | Market Intelligence Report: https://www.datamintelligence.com/buy-now-page?report=neuropathy-screening-and-diagnosis-market?rk

Regional Break out:

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/neuropathy-screening-and-diagnosis-market?rk

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.